Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2007-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.8.5.679PMID 17376022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel

  2006cited by this paper
• Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

  2006cited by this paper
• Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia

  2006cited by this paper
• Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

  2006cited by this paper
• A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

  2006cited by this paper
• Statistical Methods in Medical Research

  2006cited by this paper
• Gender and long‐term metabolic toxicities from antiretroviral therapy in HIV‐1 infected persons

  2006cited by this paper
• An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

  2006cited by this paper
• The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

  2006cited by this paper
• Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort

  2006influential reference
• [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].

  2004cited by this paper
• Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage.

  2004cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

  2004cited by this paper
• Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004)

  2004cited by this paper
• Long-Term Efficacy of a Protease Inhibitor-Sparing, Nucleoside Reverse Transcriptase Inhibitor-Limiting Antiretroviral Regimen with Nevirapine, Lamivudine, and Reduced Standard Stavudine Dosage

  2004cited by this paper
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients

  2004influential reference
• [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].

  2004cited by this paper
• Statistical Methods in Medical Research, 4th edn

  2003cited by this paper
• Lactic acidosis related to nucleoside therapy in HIV-infected patients

  2003cited by this paper
• Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999

  2002cited by this paper
• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  2002cited by this paper
• A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)

  2000cited by this paper
• A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients

  2000cited by this paper
• Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

  1999influential reference
• Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients

  1997influential reference
• Design and implementation of the stavudine parallel-track program.

  1995cited by this paper
• Dose-related activity of stavudine in patients infected with human immunodeficiency virus.

  1995influential reference
• 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.

  1993cited by this paper
• FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

  year unknowncited by this paper

• Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights

  2025cites this paper
• Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods

  2019cites this paper
• Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study

  2018cites this paper
• Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial

  2018cites this paper
• Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir

  2018cites this paper
• Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland

  2018cites this paper
• Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing

  2018influential citation
• Antiretroviral dose optimization: the future of efavirenz 400 mg dosing

  2017cites this paper
• Lipodystrophy : focus on HIV Lipodystrophy

  2017cites this paper
• Complete Phase-Out Stavudine Based Regimens in the Treatment of HIV-Infection: is it True That Stavudine Hasn’t Any Benefit Today? A Review

  2017cites this paper
• Stavudine-associated toxicity in patients on low-dose versus high-dose Stavudine in an HIV treatment cohort

  2016cites this paper
• HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings

  2015cites this paper
• ReviewGeneric and low dose antiretroviral therapy in adults and children : implication for scaling up treatment in resource limited settings

  2015cites this paper
• The Selection and Use of Essential Medicines.

  2015cites this paper
• ResearchReduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme : a retrospective observational study

  2015cites this paper
• Low dose versus high dose stavudine for treating people with HIV infection.

  2015cites this paper
• Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

  2015cites this paper
• Metabolic complications of antiretroviral therapy (ART) in a South African black population..

  2015cites this paper
• Clinical care of HIV-patients: evaluating progress and future challenges

  2014cites this paper
• Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.

  2014cites this paper
• A randomized clinical trial comparing metabolic parameters after 48 weeks of standard‐ and low‐dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV‐infected South African patients

  2014cites this paper
• Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy

  2014cites this paper
• Lactic acidosis, risk factors and predictive laboratory markers: a nested case control study in South Africa

  2014cites this paper
• Genetics of HIV-associated sensory neuropathy in black Southern Africans

  2014cites this paper
• Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands

  2013cites this paper
• Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily

  2013cites this paper
• Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges

  2013cites this paper
• The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV‐infected patients: a randomized trial

  2013cites this paper
• QUANTITATIVE ASSESSMENT OF THE PREVALENCE OF MITOCHONDRIAL TOXICITY IN HIV/AIDS PATIENTS INITIATED ON A STAVUDINE CONTAINING REGIMEN IN MOUNT AYLIFF HOSPITAL ARV CLINIC

  2013cites this paper
• Stavudine dosage reduction : effect on symptomatic hyperlactataemia and lactic acidosis in patients at Dr George Mukhari Hospital, Pretoria : scientific letter

  2013cites this paper
• Lipoatrophy in HIV-infected children on antiretroviral therapy

  2013influential citation
• Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries

  2013cites this paper
• Stavudine induced lactic acidosis, risk factors and predictive laboratory markers : a nested case-control study in South Africa.

  2012cites this paper
• Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa

  2012cites this paper
• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

  2012cites this paper
• Iatrogenic mitochondriopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors.

  2012cites this paper
• Optimisation of HIV care and service delivery: doing more with less.

  2012cites this paper
• High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study

  2012cites this paper
• Durability of First Line Antiretroviral Therapy: Reasons and Predictive Factors for Modifications in a Swaziland Cohort

  2012cites this paper
• Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

  2012cites this paper
• A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine

  2012cites this paper
• Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen

  2011cites this paper
• A retrospective cohort analysis of antiretroviral treatment modifications at the referral HIV clinic in Mbabane, Swaziland

  2011cites this paper
• Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy

  2011cites this paper
• A Risk-Factor Guided Approach to Reducing Lactic Acidosis and Hyperlactatemia in Patients on Antiretroviral Therapy

  2011cites this paper
• From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir

  2011cites this paper
• [Characteristics of antiretroviral drugs].

  2011cites this paper
• Structural studies of series HIV-1 nonnucleoside reverse transcriptase inhibitors 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-benzimidazoles with different 4-substituents

  2010cites this paper
• Structure of HIV-1 nonnucleoside reverse transcriptase inhibitors derivatives of N-benzyl-benzimidazole with different substituents in position 4

  2010cites this paper
• Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia

  2010cites this paper
• Improving first-line antiretroviral therapy in resource-limited

  2010cites this paper
• adults and children: implication for scaling up treatment in resource limited settings

  2010cites this paper
• Dose Optimisation: A Strategy to Improve Tolerability and LowerAntiretroviral Drug Prices in Low and Middle Income Countries

  2010cites this paper
• Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings

  2010cites this paper
• Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

  2010cites this paper
• Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study

  2010cites this paper
• Improving first-line antiretroviral therapy in resource-limited settings

  2010cites this paper
• d4T: keep it or abandon it?

  2010influential citation
• CHAPTER 36 – Antiretroviral agents

  2010cites this paper
• Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study

  2010influential citation
• Comparative Tolerability And Efficacy Of Stavudine 30 Mg Versus Stavudine 40 Mg In Patients On Combination Antiretroviral Therapy In Kenya

  2010cites this paper
• Effect of stavudine dosage reduction on the incidence of symptomatic hyperlactataemia/lactic acidosis in adults female HIV/AIDS infected patients treated at Dr George Mukhari Hospital

  2010influential citation
• Changing evidence on HIV treatment and prevention strategies: implications and advice for healthcare workers and National Treatment Programs in Asia

  2010cites this paper
• Insulin Resistance and the cardiometabolic syndrome in HIV infection.

  2009cites this paper
• Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study

  2009cites this paper
• LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.

  2009cites this paper
• The ABC of HIV Clinical Trials

  2009cites this paper
• Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.

  2009cites this paper
• Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women ’ s interagency HIV study

  2009cites this paper
• Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution

  2009cites this paper
• Review A new era of antiretroviral drug toxicity

  2009cites this paper
• Structural investigation of HIV-1 nonnucleoside reverse transcriptase inhibitors: 2-Aryl-substituted benzimidazoles

  2009cites this paper
• The selection and use of essential medicines.

  2009cites this paper
• Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

  2008cites this paper
• Impact of long‐term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource‐limited settings

  2008cites this paper
• Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).

  2008cites this paper
• Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.

  2008cites this paper
• Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings

  2008cites this paper
• Clinical aspects of toxicity in antiretroviral therapy

  2008cites this paper
• Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study

  2008cites this paper
• The selection and use of essential medicines.

  2008cites this paper
• A new era of antiretroviral drug toxicity

  2008cites this paper
• The marriage of science and optimized HIV care in resource-limited settings.

  2008cites this paper
• Stavudine plasma concentrations and lipoatrophy.

  2008cites this paper
• Evolution of adult antiretroviral therapy for programmatic delivery in Africa and the potential role for new therapeutic approaches

  2007cites this paper
• Clinical trials in the use of antiretroviral therapy in developing countries: results and challenges

  2007cites this paper
• Research for change: using implementation research to strengthen HIV care and treatment scale-up in resource-limited settings.

  2007cites this paper
• Estavudina en el tratamiento antirretroviral

  2007cites this paper
• [Stavudine in antiretroviral therapy].

  2007cites this paper